Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003325 · ClinicalTrials.gov registry record · Phase 3
Lymphatic Mapping in Treating Patients With Stage I or Stage II Cancer of the Vulva
A Phase 3 study of Vulvar Cancer, sponsored by Gynecologic Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 515
- Enrollment target
- 20
- Study locations
NCT00003325 is a Phase 3 study of Vulvar Cancer that has completed, run by Gynecologic Oncology Group. The registered enrollment target is 515 participants, above the 423-participant average among 17 other Vulvar Cancer trials with a reported enrollment target (22% higher). The trial reports 20 study locations across 8 states.
The verdict
NCT00003325, a Phase 3 study of Vulvar Cancer, has completed, sponsored by Gynecologic Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 515 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Lymphatic mapping may improve the ability to detect cancer of the vulva. PURPOSE: This phase III trial is studying how well lymphatic mapping works in treating patients with stage I or stage II cancer of the vulva.
Conditions Studied
Interventions
- PROCEDURE Sentinel lymph node mapping
Study Locations (20)
Indiana
- Elkhart General Hospital - Elkhart
- Indiana University Melvin and Bren Simon Cancer Center - Indianapolis
- Gynecologic Oncology of Indiana - Indianapolis
- St. Vincent Indianapolis Hospital - Indianapolis
- Howard Community Hospital - Kokomo
- CCOP - Northern Indiana CR Consortium - South Bend
- Memorial Hospital of South Bend - South Bend
- Saint Joseph Regional Medical Center - South Bend
- South Bend Clinic - South Bend
Connecticut
- Helen and Harry Gray Cancer Center at Hartford Hospital - Hartford
- Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center - Hartford
- George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus - New Britain
California
- Todd Cancer Institute at Long Beach Memorial Medical Center - Long Beach
- UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
Illinois
- Hinsdale Hematology Oncology Associates - Hinsdale
- Cardinal Bernardin Cancer Center at Loyola University Medical Center - Maywood
Arkansas
- Arkansas Cancer Research Center at University of Arkansas for Medical Sciences - Little Rock
District of Columbia
- Washington Cancer Institute at Washington Hospital Center - Washington D.C.
Florida
- Mayo Clinic - Jacksonville - Jacksonville
Georgia
- Curtis and Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center - Savannah
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 515 participants |
| Start Date | 1999-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003325
The ClinicalTrials.gov registry entry for NCT00003325 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 515 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 423-participant average among 17 other Vulvar Cancer trials with a reported enrollment target (22% higher). The listed sponsor is Gynecologic Oncology Group, which has 154 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Vulvar Cancer appearing as the primary indexed condition, and to 1 intervention - of which Sentinel lymph node mapping is the first listed.
NCT00003325 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Indiana, Connecticut, California.
Frequently Asked Questions
What is clinical trial NCT00003325 about?
NCT00003325 is a clinical study titled "Lymphatic Mapping in Treating Patients With Stage I or Stage II Cancer of the Vulva". RATIONALE: Lymphatic mapping may improve the ability to detect cancer of the vulva. PURPOSE: This phase III trial is studying how well lymphatic mapping works in treating patients with stage I or stage II cancer of the vulva.
What is the current status of trial NCT00003325?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 515 participants. The study started on 1999-12.
What conditions does trial NCT00003325 study?
This clinical trial studies the following conditions: Vulvar Cancer.
What interventions are being tested in trial NCT00003325?
The interventions under investigation include: Sentinel lymph node mapping (PROCEDURE).
Who is sponsoring clinical trial NCT00003325?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003325 being conducted?
This trial has 20 study locations across Arkansas, California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Vulvar Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ASk Questions in GYnecologic Oncology (ASQ-GYO)
RECRUITING · NA
-
Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)
RECRUITING · NA
-
Groningen International Study on Sentinel Nodes in Vulvar Cancer-III
RECRUITING · Phase 2
-
Image-Guided Gynecologic Brachytherapy
RECRUITING · NA
-
Serial MRI Scans During Radiation Therapy
RECRUITING · NA
-
Using Reiki Therapy to Improve Symptoms Associated With Brachytherapy in Patients With Gynecological Malignancies
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.